Biomarkers to Be Used for Decision of Treatment of Hypogonadal Men with or without Insulin Resistance
Male hypogonadism is a result of low testosterone levels, but patients could be insulin-sensitive (IS) or insulin-resistant (IR), showing different impaired metabolic pathways. Thus, testosterone coadministration, which is commonly used to reestablish testosterone levels in hypogonadism, must take i...
Main Author: | Lello Zolla |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Metabolites |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-1989/13/6/681 |
Similar Items
-
Plasma Metabonomics in Insulin-Resistant Hypogonadic Patients Induced by Testosterone Treatment
by: Lello Zolla, et al.
Published: (2022-07-01) -
On the Need to Distinguish between Insulin-Normal and Insulin-Resistant Patients in Testosterone Therapy
by: Lello Zolla
Published: (2022-10-01) -
Plasma Metabolomics Profile of “Insulin Sensitive” Male Hypogonadism after Testosterone Replacement Therapy
by: Lello Zolla, et al.
Published: (2022-02-01) -
Age-related hypogonadism in men with metabolic syndrome
by: Yulia Alexandrovna Tishova, et al.
Published: (2010-03-01) -
The role of hypogonadism correction in metabolic syndrome treatment in men: clinical case report
Published: (2009-06-01)